This week, biotech Oculogenex received an essential endorsement from the FDA for a therapy to treat an eye-wasting disease, marking a significant milestone in the company's strategy for a mid-stage clinical trial.
Oculogenex's collaboration with NASA and SpaceX involved sending 40 mice treated with gene therapy to the ISS on a SpaceX rocket, a groundbreaking mission funded by NASA's CASIS unit for innovative eye disease research.
Collection
[
|
...
]